FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

Launch of the 988 Lifeline was associated with significant reductions in expected suicide mortality among individuals aged 15 to 34 years.

The US Food and Drug Administration is moving to speed drug development and review by launching real-time clinical trials.

For children treated for suspected septic shock, outcomes were similar in fluid resuscitation with balanced crystalloid fluid vs 0.9% saline.

Physical activity-based interventions may help reduce chronic postsurgical pain, but current evidence is inconclusive.

The FDA accepted an NDA for a bictegravir and lenacapavir single-tablet regimen for adults with HIV-1 who have achieved virologic suppression.

Florida’s KidCare expansion has been mired in lawsuits and ongoing negotiations between the state and federal regulators.

For patients with early infection with Lyme disease, standard and modified 2-tiered testing diagnostic algorithms have low sensitivity.

A new proposal could make it easier for patients to access breakthrough medical devices through Medicare insurance.

Phase 3 ReSPECT trial data show rezafungin is noninferior to standard antimicrobial regimens for the prophylaxis of invasive ...

The FDA has accepted for Priority Review the New Drug Application for bepirovirsen for the treatment of adults with chronic hepatitis B.

UK lawmakers are taking steps to ensure young people can never legally buy cigarettes by raising the legal age to purchase tobacco.